F Ravandi

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
    Naveen Pemmaraju
    MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Houston, TX 77030, USA
    Expert Opin Investig Drugs 23:943-54. 2014
  2. ncbi request reprint Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?
    Farhad Ravandi
    MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    Curr Hematol Malig Rep 9:144-7. 2014
  3. pmc Relapsed acute myeloid leukemia: why is there no standard of care?
    Farhad Ravandi
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA Electronic address
    Best Pract Res Clin Haematol 26:253-9. 2013
  4. pmc Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
  5. pmc Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Farhad Ravandi
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4655-62. 2013
  6. ncbi request reprint Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 10:1029-36. 2012
  7. pmc Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 97:1242-5. 2012
  8. pmc Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2665-73. 2012
  9. ncbi request reprint Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial
    Michael S Mathisen
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Future Oncol 8:351-7. 2012
  10. pmc Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 34:752-6. 2010

Collaborators

Detail Information

Publications117 found, 100 shown here

  1. ncbi request reprint Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
    Naveen Pemmaraju
    MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Houston, TX 77030, USA
    Expert Opin Investig Drugs 23:943-54. 2014
    ....
  2. ncbi request reprint Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?
    Farhad Ravandi
    MD Anderson Cancer Center, University of Texas, Houston, TX, USA
    Curr Hematol Malig Rep 9:144-7. 2014
    ....
  3. pmc Relapsed acute myeloid leukemia: why is there no standard of care?
    Farhad Ravandi
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA Electronic address
    Best Pract Res Clin Haematol 26:253-9. 2013
    ....
  4. pmc Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
    ..2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR...
  5. pmc Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Farhad Ravandi
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4655-62. 2013
    ..The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD. This trial was registered at clinicaltrials.gov as #NCT01254890...
  6. ncbi request reprint Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 10:1029-36. 2012
    ..With further refinement and standardization of the assays, and the development of novel, effective, and molecularly targeted agents, monitoring of minimal residual disease is likely to be incorporated into AML guidelines...
  7. pmc Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 97:1242-5. 2012
    ..We conclude that FLT3-ITD mutations are unstable at follow up and may occur for the first time at relapse. Therefore, FLT3-ITD is not a reliable marker for minimal residual disease in acute myeloid leukemia...
  8. pmc Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2665-73. 2012
    ..IDH1 and IDH2 gene mutations are novel, recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia (AML)...
  9. ncbi request reprint Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial
    Michael S Mathisen
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Future Oncol 8:351-7. 2012
    ..The data available to date is analyzed and future perspectives regarding the development of this agent is discussed...
  10. pmc Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 34:752-6. 2010
    ..017). Overall, patients with mutated FLT3 had a shorter survival from the time of relapse compared to those with FLT3-WT (P<0.001). The adverse prognostic impact of FLT3 mutations appears to persist beyond the initial treatment...
  11. pmc Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5746-51. 2009
    ..Outcome of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with chromosome 5 and 7 abnormalities (excluding del 5[q]) has been poor, with <10% of patients alive at 2 years...
  12. pmc Primary refractory acute myeloid leukaemia - in search of better definitions and therapies
    Farhad Ravandi
    Department of Leukaemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 155:413-9. 2011
    ..Novel strategies and new agents directed at the biology of the disease and the mechanisms of resistance are needed...
  13. ncbi request reprint Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors
    Farhad Ravandi
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma Leuk 11:198-203. 2011
    ..Patients who relapse during treatment with dasatinib frequently carry the T315I mutation of BCR-ABL. Future regimens combining dasatinib with an agent able to inhibit this mutation may further improve outcome...
  14. ncbi request reprint Chemo-immunotherapy for hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 52:72-4. 2011
    ..Alternatively, it may be possible to identify patients who are more likely to relapse using pretreatment characteristics such as the mutational status of IGHV and apply these strategies solely to them...
  15. ncbi request reprint Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  16. ncbi request reprint Treatment of acute myeloid leukemia in older adults: time to reflect?
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:579-80. 2006
  17. ncbi request reprint Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:5818-23; quiz 6153. 2010
    ..Alternative strategies are needed for these patients...
  18. ncbi request reprint Progress in the treatment of acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1900-10. 2007
    ....
  19. ncbi request reprint First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:2070-7. 2010
    ..The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793...
  20. ncbi request reprint Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma
    Farhad Ravandi
    University of Texas MD Anderson Cancer Center, Department of Leukaemia, Unit 428, 1515 Holcombe Boulevad, Houston, TX 77030, USA
    Expert Opin Investig Drugs 15:1601-13. 2006
    ..This review summarises the preclinical, clinical and pharmacokinetic investigations with these novel agents...
  21. ncbi request reprint Alemtuzumab in CLL and other lymphoid neoplasms
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer Invest 24:718-25. 2006
    ..Effective antibiotic prophylaxis can limit the incidence of infections, which are the major side effect associated with the profound lymphopenia occurring as a result of treatment with this agent...
  22. pmc Philadelphia chromosome-positive acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 23:1043-63, vi. 2009
    ..The introduction of effective TKIs in the treatment of Ph+ ALL has introduced several avenues of research in a disease that was hitherto difficult to treat...
  23. doi request reprint Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  24. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
    ..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...
  25. ncbi request reprint Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)
    F Ravandi
    Leukemia Department, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Res 31:791-7. 2007
    ..04). Other mechanisms may be responsible for abnormal phosphorylation of FLT3 and inhibitors of FLT3 should also be investigated in patients without mutations...
  26. ncbi request reprint Infections associated with purine analogs and monoclonal antibodies
    Farhad Ravandi
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 4095, USA
    Blood Rev 19:253-73. 2005
    ..Furthermore, risk-based strategies to decrease the incidence of these infectious complications have been proposed...
  27. ncbi request reprint Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin
    Farhad Ravandi
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 30:103-5. 2006
    ..Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role in this setting. However, the associated immunosuppression is a concern in patients with viral-mediated disease...
  28. ncbi request reprint Arsenic trioxide: expanding roles for an ancient drug?
    F Ravandi
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Leukemia 18:1457-9. 2004
  29. ncbi request reprint Hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S254-9. 2009
    ..Whether such strategies of chemoimmunotherapy would lead to further improvements in the outcome of patients with HCL needs to be further investigated...
  30. ncbi request reprint Immune defects in patients with chronic lymphocytic leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 4095, USA
    Cancer Immunol Immunother 55:197-209. 2006
    ..Furthermore, the understanding of the mechanisms of immune dysfunction in CLL is of pivotal importance in the novel immune-based therapeutic strategies currently under development...
  31. ncbi request reprint Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:3818-23. 2011
    ..Median survival duration has not been reached (range, 2+-64+ months). Treatment with cladribine followed by rituximab is effective tk;4and may increase CR rate. This study was registered at www.clinicaltrials.gov as NCT00412594...
  32. ncbi request reprint Mature T-cell leukemias
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1808-18. 2005
    ..Herein, we review the clinical and pathological features of mature T-cell leukemias...
  33. ncbi request reprint New agents in acute myeloid leukemia and other myeloid disorders
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:441-54. 2004
    ..Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized...
  34. ncbi request reprint Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Mayo Clin Proc 80:1660-74. 2005
    ..In this article, we review the diagnostic and clinical features of mature B-cell and T-cell lymphoproliferative disorders that commonly have a leukemic presentation...
  35. doi request reprint Modern treatment programs for adults with acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Hematol Malig Rep 2:169-75. 2007
    ..It is likely that we will further refine therapeutic approaches and improve patient outcome through the translation of biologic and molecular discoveries into effective and risk-adapted strategies...
  36. ncbi request reprint T-cell prolymphocytic leukemia: a single-institution experience
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Lymphoma Myeloma 6:234-9. 2005
    ..The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias...
  37. ncbi request reprint Eradication of leukemia stem cells as a new goal of therapy in leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:340-4. 2006
    ..Ongoing research is likely to reveal the molecular mechanisms responsible for LSC characteristics and lead to novel strategies for eradicating leukemia...
  38. ncbi request reprint Eradication of minimal residual disease in hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:4658-62. 2006
    ..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy...
  39. ncbi request reprint Role of cytokines in the treatment of acute leukemias: a review
    F Ravandi
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:563-71. 2006
    ..In this review, we summarize the clinical experience with these growth factors in treating acute leukemias...
  40. ncbi request reprint Alemtuzumab
    Farhad Ravandi
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, Houston, TX 77030 4095, USA
    Expert Rev Anticancer Ther 5:39-51. 2005
    ..Despite this, and with appropriate and more effective antibiotic prophylaxis, it is likely that we will witness an expansion of the role of alemtuzumab in the future...
  41. ncbi request reprint Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution
    F P S Santos
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leukemia 23:2275-80. 2009
    ..The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors...
  42. pmc Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 32:1468-71. 2008
    ..The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL...
  43. ncbi request reprint Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  44. ncbi request reprint Activity of alemtuzumab in patients with CD52-positive acute leukemia
    Raoul Tibes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2645-51. 2006
    ..Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)...
  45. ncbi request reprint T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
    ..Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients...
  46. ncbi request reprint Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
    J Hoellenriegel
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leukemia 26:1576-83. 2012
    ....
  47. ncbi request reprint Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
    F Ravandi
    Department of Hematology, University of Texas MD Anderson Cancer Center, Houston 77027, USA
    Bone Marrow Transplant 27:1221-5. 2001
    ..Current response data should encourage further study of this drug, either alone or in combination with other agents, for treatment of relapsed acute leukemia after an allogeneic transplant...
  48. ncbi request reprint A prognostic score for patients with lower risk myelodysplastic syndrome
    G Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:538-43. 2008
    ..2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention...
  49. ncbi request reprint Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome
    L de Padua Silva
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 43:839-43. 2009
    ..Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in MDS and should be evaluated in a prospective trial...
  50. ncbi request reprint A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  51. pmc Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia
    Kumudha Balakrishnan
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:886-92. 2010
    ..Forodesine has biologic activity in CLL; pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population...
  52. ncbi request reprint Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy
    Ravin Garg
    Department of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:2147-54. 2009
    ....
  53. ncbi request reprint Novel agents in acute myeloid leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 12:77-91. 2006
    ..Targeted therapy has improved outcomes in some patients. Most of the new agents are less toxic then their predecessors, and they can be used in combination with the more intensive traditional regimens...
  54. ncbi request reprint Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  55. ncbi request reprint A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
    ..Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP...
  56. ncbi request reprint Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  57. pmc Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia
    Paul M Armistead
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston Texas, USA
    Biol Blood Marrow Transplant 15:1431-8. 2009
    ..Our data suggest that HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years...
  58. ncbi request reprint A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:72-82. 2010
    ..The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting...
  59. doi request reprint Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation
    Y Chen
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 27:836-42. 2013
    ..001) and relapse-free survival (P<0.001) in patients with AML and 11q23 abnormalities...
  60. ncbi request reprint Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance
    F Ravandi
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1964-72. 2001
    ..The influence of these cellular proteins and caspase-3 activity on apoptosis in CML is complex and merits further investigation...
  61. ncbi request reprint Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:2912-21. 2009
    ..Dasatinib is a 325-fold more potent inhibitor of Bcr-Abl than imatinib and has been associated with high rates of durable responses in patients with CML in chronic phase (CP) after imatinib failure...
  62. ncbi request reprint Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:101-6. 2009
    ..Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children...
  63. ncbi request reprint The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  64. ncbi request reprint Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
    ..Liposomal cytarabine given via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barrier such as high-dose MTX and cytarabine can result in significant neurotoxicity...
  65. ncbi request reprint Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  66. pmc Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells
    Kumudha Balakrishnan
    Department of Experimental Therapeutics, Unit 71, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:2392-8. 2006
    ..Based on these data, a phase 2 clinical trial of forodesine has been initiated for CLL patients...
  67. ncbi request reprint Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:516-8. 2008
    ..These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies...
  68. ncbi request reprint Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome
    R Garg
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 23:1297-302. 2009
    ..Grade III/IV toxicities were mainly cytopenias and neutropenic fever. Combination of rATG, cyclosporine and G-CSF is safe and effective as first-line treatment of AA and has significant activity in low-risk MDS...
  69. pmc High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia
    Marco Herling
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 111:328-37. 2008
    ..Experimental introduction and knockdown of TCL1 influence the kinetics and strength of TCR-mediated AKT activation. We propose that in T-PLL, TCL1 represents a highly regulated, targetable modulator of TCR-mediated AKT growth signaling...
  70. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  71. ncbi request reprint The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  72. ncbi request reprint Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Fabio P S Santos
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:303-12. 2010
    ..Further studies are required to determine whether there might be a minimum adequate dose of these agents...
  73. ncbi request reprint Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors
    Fabio P S Santos
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:16-26. 2009
    ..Resistance to multiple TKIs does occur, particularly in patients with the T315I mutation. Several new agents are in development including new TKIs, aurora kinase inhibitors and homoharringtonine...
  74. ncbi request reprint Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:880-4. 2006
    ..51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease...
  75. doi request reprint A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintas-Cardama
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leukemia 22:965-70. 2008
    ..0014) and returned to 50% at the end of the first 28-day cycle (P=0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity...
  76. pmc Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Gautam Borthakur
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 96:62-8. 2011
    ..A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  77. pmc Late relapses in acute myeloid leukemia: analysis of characteristics and outcome
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 51:778-82. 2010
    ..4 months (range, 1-39). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone...
  78. ncbi request reprint Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5568-74. 2010
    ..The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics...
  79. ncbi request reprint Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77230 1402, USA
    J Clin Oncol 28:2755-60. 2010
    ..Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS)...
  80. doi request reprint Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:572-80. 2011
    ..Interferon alpha (IFN α) is efficacious in CML likely due to its immunomodulatory properties, and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor (GM-CSF)...
  81. ncbi request reprint Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1556-60. 2007
    ..The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented...
  82. pmc Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
    ..In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks...
  83. ncbi request reprint Purine analogues in advanced T-cell lymphoid malignancies
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:S27-34. 2006
    ..Future studies of purine analogues should evaluate patients who are less heavily pretreated and combination therapy with other agents such as alemtuzumab should be investigated in order to prolong the duration of disease remission...
  84. ncbi request reprint Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission
    Masamitsu Yanada
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2756-60. 2007
    ..Potential cure of acute myeloid leukemia (AML) is now a widely accepted idea, but it is uncertain whether there is heterogeneity in the failure rate in patients once they have been in complete remission (CR) for various periods of time...
  85. ncbi request reprint Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1351-61. 2008
    ....
  86. ncbi request reprint Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 115:3217-21. 2009
    ..Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities...
  87. ncbi request reprint Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
    Marcos de Lima
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 97:1242-7. 2003
    ..Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation...
  88. ncbi request reprint Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  89. pmc Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:475-80. 2010
    ..These results could be used in assessing the efficacy of new treatments aimed at improving CR durations and survival post salvage therapy...
  90. ncbi request reprint The JAK-STAT pathway: a therapeutic target in hematological malignancies
    A Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 70230 1402, USA
    Curr Cancer Drug Targets 6:671-9. 2006
    ..This review describes the pathophysiological role of this pathway in hematological malignancies and the potential benefits of JAK-STAT inhibition...
  91. ncbi request reprint Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
    Hillary Prescott
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Houston, USA
    Expert Opin Emerg Drugs 16:407-23. 2011
    ..Therefore, substantial interest in FLT3 as a therapeutic target has led to the development of several promising inhibitors that target this tyrosine kinase...
  92. ncbi request reprint A potential role of ruxolitinib in leukemia
    Kiran Naqvi
    University of Texas M D Anderson Cancer Center, Department of Leukemia, Houston, USA
    Expert Opin Investig Drugs 20:1159-66. 2011
    ..Further studies of ruxolitinib, in patients with acute and chronic leukemias, are now needed to establish the clinical usefulness of this promising drug...
  93. ncbi request reprint Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
    Yiming Chen
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:2507-13. 2011
    ....
  94. ncbi request reprint Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    ..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
  95. ncbi request reprint Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  96. doi request reprint Clofarabine combinations as acute myeloid leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2090-6. 2008
    ..Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine...
  97. ncbi request reprint Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia
    Masamitsu Yanada
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Leuk Res 32:1505-9. 2008
    ..38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML...
  98. ncbi request reprint Monoclonal antibody therapy for hairy cell leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, 77030, USA
    Hematol Oncol Clin North Am 20:1125-36. 2006
    ..Appropriate pharmacologic investigation, use of antigen modulation, and assessments of soluble antigen levels should be considered with future clinical trial s of MoAb's in HCL to optimize therapeutic strategies...
  99. ncbi request reprint Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
    Mohamad A Hussein
    Cleveland Clinic Multiple Myeloma Research Program, Cleveland, OH 44195 0000, USA
    Br J Haematol 125:470-6. 2004
    ..These data indicate that arsenic trioxide is active and reasonably well tolerated as a single-agent salvage therapy, even in patients with late-stage, relapsed and refractory MM...